Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment returns to a record 8 billion euros ($8.66 billion) in 2024, it said on ...

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.

"2024 was a very strong year for Novo Holdings, with our investment portfolio delivering its best ever performance," CEO Kasim Kutay said in a statement. Kutay said the company would focus this ...

Novo Holdings CEO Kasim Kutay said that 2024 was a very strong year for the company, with its investment portfolio delivering the best performance and the Novo Group companies contributing ...

Also Read: Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug Novo Holdings CEO Kasim Kutay called 2024 “a very strong year” since the portfolio generated returns of 18%. That’s ...

Novo Holdings CEO Kasim Kutay says China has "really moved up the value chain" in healthcare. "We've seen many others investing in China because of the leap that they're taking from an innovation and ...

Novo Holdings is the owner of Novo Nordisk, famous for its diabetes medicine Ozempic and obesity treatment Wegovy. Novo Holdings CEO Kasim Kutay says China has "really moved up the value chain" in ...

LONDON/COPENHAGEN, April 2 (Reuters) - Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk (NOVOb.CO), opens new tab, nearly doubled annual income and investment returns ...